Parallel Advisors LLC Has $375,000 Position in Sanofi (NASDAQ:SNY)

Parallel Advisors LLC lifted its stake in shares of Sanofi (NASDAQ:SNY) by 14.6% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 7,732 shares of the company’s stock after acquiring an additional 987 shares during the period. Parallel Advisors LLC’s holdings in Sanofi were worth $375,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. POM Investment Strategies LLC acquired a new position in Sanofi during the second quarter worth $25,000. Frazier Financial Advisors LLC acquired a new position in Sanofi during the fourth quarter worth $28,000. Larson Financial Group LLC raised its holdings in Sanofi by 480.8% during the first quarter. Larson Financial Group LLC now owns 604 shares of the company’s stock worth $29,000 after buying an additional 500 shares during the last quarter. Register Financial Advisors LLC acquired a new position in Sanofi during the first quarter worth $29,000. Finally, Johnson Financial Group Inc. acquired a new position in Sanofi during the fourth quarter worth $31,000. Institutional investors and hedge funds own 10.04% of the company’s stock.

Sanofi Price Performance

SNY opened at $56.91 on Wednesday. The firm has a market cap of $144.14 billion, a P/E ratio of 28.60, a PEG ratio of 1.60 and a beta of 0.60. The firm has a 50-day moving average of $53.95 and a 200 day moving average of $50.30. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00. Sanofi has a fifty-two week low of $42.63 and a fifty-two week high of $58.97.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings results on Thursday, July 25th. The company reported $0.93 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.05. The company had revenue of $10.75 billion during the quarter, compared to analyst estimates of $16.86 billion. Sanofi had a net margin of 9.60% and a return on equity of 26.29%. The firm’s revenue for the quarter was up 7.8% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.95 earnings per share. On average, research analysts expect that Sanofi will post 4.25 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on SNY shares. Argus upped their price objective on shares of Sanofi from $55.00 to $60.00 and gave the stock a “buy” rating in a report on Friday, July 26th. StockNews.com lowered shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, September 11th. Three analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $57.50.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.